Institutional shares held 60.9 Million
27.7K calls
11.3K puts
Total value of holdings $2.15B
$976K calls
$398K puts
Market Cap $1.9B
53,495,300 Shares Out.
Institutional ownership 113.85%
# of Institutions 282


Latest Institutional Activity in SUPN

Top Purchases

Q3 2024
American Century Companies Inc Shares Held: 1.04M ($37.1M)
Q3 2024
Pacer Advisors, Inc. Shares Held: 1.75M ($62.3M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 900K ($32M)
Q3 2024
Hsbc Holdings PLC Shares Held: 250K ($8.9M)
Q3 2024
Woodline Partners LP Shares Held: 189K ($6.7M)

Top Sells

Q3 2024
Armistice Capital, LLC Shares Held: 5.1M ($181M)
Q3 2024
Ashford Capital Management Inc Shares Held: 544K ($19.3M)
Q3 2024
Bank Of Montreal Shares Held: 7.12K ($253K)
Q3 2024
Invesco Ltd. Shares Held: 486K ($17.3M)
Q3 2024
Mutual Of America Capital Management LLC Shares Held: 203K ($7.2M)

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.


Insider Transactions at SUPN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
575K Shares
From 19 Insiders
Grant, award, or other acquisition 31.1K shares
Exercise of conversion of derivative security 527K shares
Other acquisition or disposition 16.5K shares
Sell / Disposition
504K Shares
From 14 Insiders
Payment of exercise price or tax liability 45.2K shares
Open market or private sale 443K shares
Other acquisition or disposition 16.5K shares

Track Institutional and Insider Activities on SUPN

Follow SUPERNUS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN